<DOC>
	<DOCNO>NCT02656043</DOCNO>
	<brief_summary>Phase 1/2 study enrol 48 healthy volunteer Phase 1 follow 150 subject acne vulgaris Phase 2 .</brief_summary>
	<brief_title>A Safety , Tolerability , Efficacy Exposure Study XEN801 Topical Gel</brief_title>
	<detailed_description>Phase 1/2 study enrol 48 healthy volunteer follow 150 subject acne vulgaris . Data Phase 1 stage review progressing Phase 2 . Phase 1 open label study determine safety , tolerability XPF-005 topical gel exposure XEN801 ( active ingredient ) . Four cohort 12 healthy volunteer receive different dose volume XPF-005 gel Placebo gel face back 14 21 day . Safety assessment complete PK sample collect study visit . Phase 2 randomize , double-blind , vehicle-controlled , parallel-group study determine safety , tolerability , efficacy XPF-005 topical gel exposure XEN801 ( active ingredient ) . Approximately 150 subject acne vulgaris apply XPF-005 match placebo gel face 12 week . Safety efficacy assessment complete PK sample collect study visit . Safety assessment include local skin tolerability assessment , vital sign , physical examination , 12-lead ECG , safety laboratory blood urine adverse event reporting . Efficacy assessment include acne lesion count Investigator 's Global Assessment ( IGA ) .</detailed_description>
	<mesh_term>Acne Vulgaris</mesh_term>
	<criteria>Key 1 . Aged 18 50 , inclusive 2 . Male female , agree comply contraceptive requirement 3 . Signed Informed Consent Form 4 . Clinical diagnosis facial acne vulgaris define : 25 75 inflammatory lesion , 20 120 noninflammatory lesion , IGA score â‰¥3 5 . Agree refrain use topical acne treatment face oral acne treatment . Topical acne treatment significant measurable systemic absorption permit treatment back , shoulder , chest Key 1 . Known sensitivity topical dermal product , include alcohol 2 . Female breast feeding , pregnant , plan become pregnant 3 . Any skin condition face acne vulgaris 4 . Two active nodular lesion 5 . Excessive facial hair would interfere evaluation safety diagnosis assessment acne vulgaris 6 . Use tanning beds/booths , excessive sun exposure 7 . Use overthecounter topical medication treatment acne vulgaris face within 14 day baseline 8 . Use systemic corticosteroid , antibiotic , antiacne drug , antiinflammatory drug ( NSAIDs permit ) prescription topical retinoid use face within 28 day prior baseline 9 . Initiation hormonal therapy dose change hormonal therapy within 12 week prior baseline . 10 . Use androgen receptor blocker ( eg , spironolactone , flutamide ) within 12 week prior baseline 11 . Use oral retinoid ( eg , isotretinoin , alitretinoin ) within 12 month prior baseline vitamin A supplement &gt; 10,000 units/day within 6 month prior baseline 12 . Facial procedure ( eg , microdermabrasion , chemical laser peel ) within 8 week prior baseline 13 . Photodynamic therapy within 12 week prior baseline 14 . Any reason would make subject , opinion Investigator Sponsor , unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>